CIPDB › China Industry › Chemicals › Pharmaceutical Intermediate
Factory Supply Raw Material Aminophylline Powder Aminophylline1
Pharmaceutical IntermediateAminophyllineAminophylline Powder
Xi'an CQ-Moonlight Pharmaceutical Ltd.
Preview:
Product DescriptionFactory Supply Raw Material Aminophylline Powder AminophyllineProduct DescriptionProduct DetailsProduct NameAminophyllineCAS No.317-34-0MFC16H24N10O4MW420.42600AppearanceWhite or slightly yellow powderAminophylline is a complex of theophylline and Ethylenediamin in a 2:1 molar ratio, appearing as a white or slightly yellowish crystalline powder with a faint ammoniacal odor. This pharmaceutical compound has a molecular formula of C16H24N10O4 and molecular weight of 420.43 g/mol, consisting of approximately 79% theophylline and 21% Ethylenediamin by weight. The compound demonstrates good water solubility (1:5 in water at 25°C) due to its ionic nature, but shows limited solubility in alcohol and is practically insoluble in ether. Aminophylline exhibits stability under normal storage conditions when protected from light and moisture, though it gradually loses Ethylenediamin upon exposure to air. The crystalline structure features coordination bonds between theophylline molecules and Ethylenediamin, which significantly enhances the water solubility compared to theophylline alone. Analytical characterization typically involves HPLC with UV detection at 270 nm, showing characteristic peaks for both theophylline and Ethylenediamin components. The pharmaceutical-grade material contains not less than 84% theophylline and 13.5-15.5% Ethylenediamin, with strict limits on related substances including Caffein (≤0.15%) and other xanthine derivatives. The compound's aqueous solutions are alkaline (pH ≈ 9-10) due to the presence of Ethylenediamin.Application&FunctionAminophylline functions primarily as a bronchodilator through inhibition of phosphodiesterase enzymes and antagonism of adenosine receptors, resulting in relaxation of bronchial smooth muscles and improved airflow. This dual mechanism makes it clinically valuable for treating respiratory conditions including asthma, chronic obstructive pulmonary disease, and bronchospasm associated with chronic bronchitis. The compound is administered intravenously in acute situations (loading dose of 5-6 mg/kg followed by maintenance infusion of 0.4-0.9 mg/kg/hour) and orally for chronic management (200-400 mg every 6-8 hours). In neonatal medicine, aminophylline serves as a respiratory stimulant for treating apnea of prematurity at lower doses (5-8 mg/kg loading followed by 1.5-3 mg/kg every 8-12 hours). The Ethylenediamin component enhances both the solubility and bioavailability of theophylline, allowing more predictable pharmacokinetics compared to theophylline alone. Therapeutic drug monitoring is essential due to its narrow therapeutic index (10-20 μg/mL serum concentration). Additional applications include adjunctive treatment for cardiac asthma and bradycardia, where its positive inotropic and chronotropic effects are beneficial. The compound's ability to inhibit inflammatory mediators has also prompted research into potential applications for inflammatory lung conditions. Careful dose titration is required due to potential adverse effects including nausea, tachycardia, and central nervous system stimulation at higher concentrations.SpecificationCertificate of Analysis
Purchasing Agent
Note: Send your message to supplier or manufacturer.
Welcome to our Professional and comprehensive procurement services...